Revenue Update on Cytosorbents Corp(NASDAQ:CTSO)

Cytosorbents Corp(NASDAQ:CTSO) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $2.22M. Analysts estimated a revenue of $2.18M. Earnings per share were $-0.12. Analysts had estimated an EPS of $-0.09.

Cytosorbents Corp (CTSO) made into the market gainers list on Wednesdays trading session with the shares advancing 0.84% or 0.04 points. Due to strong positive momentum, the stock ended at $4.78, which is also near the day’s high of $4.81. The stock began the session at $4.76 and the volume stood at 33,450 shares. The 52-week high of the shares is $8.1 and the 52 week low is $3.11. The company has a current market capitalization of $122 M and it has 2,54,37,766 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 9, 2016, Michael G. Bator (director) purchased 3,000 shares at $4.88 per share price.Also, On Jan 13, 2016, Investment Fund, Lp Njtc (10% owner) sold 124,281 shares at $4.27 per share price.On Dec 14, 2015, Kathleen P. Bloch (CFO) purchased 2,125 shares at $7.05 per share price, according to the Form-4 filing with the securities and exchange commission.

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company utilizes blood purification to modulate inflammation for treating multiple organ failure illnesses and cardiac surgery. The Company’s purification technologies are based on biocompatible porous polymer beads that can remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s product CytoSorb is approved in the European Union as an extracorporeal cytokine filter designed to reduce the cytokine storm that could cause inflammation organ failure and death in common critical illnesses such as sepsis burn injury trauma lung injury and pancreatitis. The Company also has other products under development based upon its blood purification technology including HemoDefend ContrastSorb DrugSorb BetaSorb and others. In addition CytoSorb can be used in conditions such as cardiac surgery autoimmune disease flares among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Cytosorbents Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cytosorbents Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.